Senseonics Holdings (SENS) Earnings Date & Reports

Key Takeaways

• Senseonics reported third quarter 2026 net revenue of $19.6 million, up roughly 140% year over year and well above consensus estimates near $16.2 million.
• U.S. revenue climbed about 160% to $16.8 million, while revenue outside the U.S. rose roughly 65% to $2.8 million.
• Gross margin expanded to about 62% from 43% a year earlier, lifting gross profit to $12.1 million.
• Net loss widened to $32.7 million, or $0.50 per share, versus $19.5 million, or $0.43 per share, in the prior-year quarter.
• Management raised full-year 2026 revenue guidance to $68 million–$70 million and now expects gross margin above 60%.
• Cash, restricted cash, and short-term investments totaled $126.6 million as of September 30, 2026.
• For more on SENS, explore its Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• Discover new opportunities with Trending AI Robots.

Earnings Context and Why It Matters

Senseonics is a diabetes technology company redefining continuous glucose monitoring (CGM) with its long-term, implantable Eversense sensor. This quarter matters because it tests whether the company's Eversense 365 system—the only CGM offering a full year on a single sensor—can convert rising patient adoption into durable revenue growth. After bringing commercial operations in-house from its former partner Ascensia, Senseonics has posted consecutive record quarters, and investors are watching closely to see whether that momentum can be sustained across the United States and a newly launched European rollout while losses remain elevated.

Reported Results

For the third quarter ended September 30, 2026, Senseonics reported net revenue of $19.6 million, up approximately 140% from $8.1 million in the prior-year period and ahead of consensus estimates. U.S. revenue grew about 160% to $16.8 million, while revenue outside the U.S. rose about 65% to $2.8 million. Gross profit reached $12.1 million, with gross margin of about 62%, up from 43% a year earlier, reflecting a favorable shift toward higher-priced bundled-pay sales and early Eversense 365 sales in Europe.

Net loss widened to $32.7 million, or $0.50 per share, from $19.5 million, or $0.43 per share, a year earlier, driven by higher research and development (R&D) and selling, general, and administrative (SG&A) spending tied to commercialization. Management raised full-year 2026 revenue guidance to $68 million–$70 million, implying 93%–98% growth, and lifted its gross margin outlook to more than 60%.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters covering industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps surface trade ideas, trending names, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to streamline your research.

Market Reaction and Investor Sentiment

Investor sentiment around Senseonics has strengthened through 2026 as the Eversense 365 rollout gained pace. Shares have climbed sharply over the trailing twelve months, and the post-earnings reaction reflected enthusiasm for the raised revenue forecast and the second consecutive quarterly revenue record. Analysts noted that revenue beat estimates by a wide margin, while the per-share loss was roughly in line with expectations. The key drivers of optimism are accelerating new patient starts—roughly nine out of ten new insertions involve patients switching from a competing sensor—and the expanding EON Care insertion network, which accounted for more than 40% of U.S. insertions in the quarter.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will be watching whether Senseonics can sustain its commercial momentum while managing an elevated cost base. The company's new partnerships are a central catalyst: an integration with Sequel's twiist insulin pump is already live, and a commercial launch with Beta Bionics' iLet Bionic Pancreas is expected in the coming weeks, potentially adding an automated insulin delivery (AID) option that could broaden the addressable patient pool.

On the product pipeline, Senseonics began first-in-human testing of its "Freedom" system in late October 2026. Freedom is designed to be the first CGM with no on-body component, and the company is targeting a pivotal study in 2027 and a potential launch in 2028. Progress on Freedom, along with the Gemini program, will be important longer-term drivers to monitor.

Finally, investors should track margin trends, operating expenses, and cash utilization. Management expects full-year operating expenses slightly above its prior $150 million–$160 million range and has hinted that 2027 revenue could approach $100 million. Gross margin direction, reimbursement mix, and the pace of European adoption will all help determine whether the current growth story translates into a narrower path toward profitability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations